论文部分内容阅读
【目的】探讨本地区尿路感染大肠埃希菌检出率及耐药情况，为临床合理用药提供依据。【方法】对2010年1月至2011年12月本院尿路感染的住院患者中段尿分离培养出的208株大肠埃希菌的耐药性及超广谱β-内酰胺酶（ ESBLs）菌株进行统计分析。【结果】分离鉴定208株大肠埃希菌，其中产ESBLs株109株，占52．4％，产ESBLs大肠埃希菌对美罗培南、亚胺培南、头孢哌酮/舒巴坦、阿米卡星、哌拉西林/他唑巴坦及头孢西丁保持较高的敏感性，产ESBLs大肠埃希菌耐药率明显高于非ESBLs株。【结论】尿路感染大肠埃希菌耐药现象比较严重，特别是产ESBLs株，应当加强对产ESBLs菌株及耐药情况的监测，对临床用药和控制耐药菌株的传播有重要意义。“,”[Objective] To explore the detection rate and drug resistance of Escherichia coli in urinary tract infection of our region in order to provide the evidence for clinical rational administration .[Methods]The drug susceptibility results of 208 strains of Escherichia coli and extended-spectrum beta-lactamases(ESBLs) isolated from medistream urine of inpatients with urinary tract infection in our hospital between Jan .2010 and Dec . 2011 were analyzed .[Results] The 208 strains of Escherichia coli were isolated and identified .Among them , 109 strains were producing-ESBLs(52 .4% ) .The sensitivity of producing-ESBLs from Escherichia coli to Mer-openem ,imipenem ,Cefoperazone/sulbactam ,Amikacin ,piperacillin/tazobactam and cefoxitin were higher , and the drug resistance rate of producing-ESBLs strains from Escherichia coli was obviously higher than that of non-ESBLs strains .[Conclusion] The drug resistance of Escherichia coli in urinary tract infection is high ,es-pecially for producing ESBLs strains .Strengthening the monitoring of producing ESBLs strains is of important significance for clinical medication and the controlling of the spread of resistant strains .